SixPeaks Bio’s financing: the advisors

Walder Wyss advised SixPeaks Bio in securing  USD 30 million in Series A financing led by founding investor Versant Ventures and a strategic collaboration with AstraZeneca. The latter, advised by Lenz & Staehelin, will provide additional, non-dilutive financing of up to USD 80 million over the next two years. Moreover, AstraZeneca has certain exclusive rights to acquire SixPeaks during this period. 

Specifically, with a pipeline of therapies for healthy weight loss, including a potentially best-in-class dual-specific antibody targeting activin type IIA and B receptors, SixPeaks Bio today emerged from stealth mode.

Walder Wyss’ team

Walder Wyss advised SixPeaks Bio on all swiss legal aspects of the transaction with a team comprising corporate / M&A and venture capital partner Alexander Gutmans (pictured above) corporate / M&A and venture capital managing associate Karina Tschon, tax managing associate Michelle Bruni, corporate / M&A and venture capital associate Lucas Maurer and corporate / M&A and venture capital associate Simon Olstein.

Laenz & Staehelin’s team

L&S operated with a team comprising partner Tino Gaberthüel (pictured right), associate Raphael Fries (both corporate/M&A), partner Patrick Schärli (regulatory), partner Anja Affolter Marino (employment/pension), partner Peter Ling (IP), partner Pascal Hinny (tax) and counsel Franziska Stadtherr (participation plans).

SixPeaks Bio

SikPeaks Bio, founded in 2022 at Versant’s Ridgeline Discovery Engine in the Basel Technology Park, aims at developing improved therapies for healthy weight loss.